-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Oglufanide
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/38101-59-6.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 38101-59-6 |
| Description | Oglufanide is a VEGFR inhibitor that may suppress angiogenesis. |
Product Information
| Synonyms | IM 862; IM-862; IM862 NSC 334073; NSC-334073; NSC334073; Thymogen; L-glutamyl-L-tryptophan; alpha-Glutamyltryptophan; L-a-Glutamyl-L-tryptophan |
| IUPAC Name | (4S)-4-amino-5-[[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid |
| Molecular Weight | 333.34 |
| Molecular Formula | C16H19N3O5 |
| Canonical SMILES | C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)NC(=O)C(CCC(=O)O)N |
| InChI | InChI=1S/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/m0/s1 |
| InChIKey | LLEUXCDZPQOJMY-AAEUAGOBSA-N |
| Boiling Point | 738.9±60.0 °C at 760 mmHg |
| Melting Point | 121-122°C |
| Flash Point | 400.7°C |
| Purity | >98% |
| Density | 1.428 g/cm3 |
| Solubility | Soluble in DMSO. |
| Appearance | Solid Powder |
| Shelf Life | 2 years |
| Storage | Store at -20°C |
| Complexity | 484 |
| Exact Mass | 333.13247072 |
| Index Of Refraction | 1.659 |
| In Vitro | Oglufanide (IM862) (1-1000 μg/mL) exhibits dose dependent inhibition of angiogenesis in the chorioallantoic membrane assay with complete inhibition of β-FGF and VEGF-induced angiogenesis. Oglufanide (L-glu-L-trp) (0-1000 μg/mL; 5 days) has no effect on the viability of either the tumor cell lines or HUVECs. |
| In Vivo | Oglufanide (L-glu-L-trp) (1-100 mg/kg/day; s.c.; 10 days) has antitumor activity in immunocompetent and immunodeficient mice. |
| PSA | 149.00000 |
| Target | VEGFR; HCV; Endogenous Metabolite |
| Vapor Pressure | 6.29E-23mmHg at 25°C |
| XLogP3-AA | -2.7 |